Mild cognitive impairment
Mild cognitive impairment (MCI) is a clinical syndrome characterized by measurable cognitive decline that is greater than expected for age but does not yet meet criteria for dementia.
Mild cognitive impairment (MCI) is a clinical syndrome characterized by measurable cognitive decline that is greater than expected for age but does not yet meet criteria for dementia. It is commonly described as an intermediate state between normal cognitive aging and dementia, and it is often used in research and clinical practice as a prodromal or risk state for neurodegenerative disease, especially Alzheimer disease. Individuals with MCI may have isolated memory impairment or deficits in other cognitive domains, while daily functional independence is largely preserved.
Biologically and medically, MCI is important because it is a major target for early detection, risk stratification, and intervention. Recent research has linked MCI to Alzheimer disease-related pathology, vascular brain injury, obstructive sleep apnoea, hearing loss, type 2 diabetes, and broader brain-aging exposures. It is also a frequent endpoint in studies of biomarkers, imaging, digital health tools, and preventive therapies aimed at slowing progression to dementia or improving cognitive and functional outcomes.
Where the papers sit
11 papers from the last 6 months study mild cognitive impairment directly · updated from PubMed 16 Nov 2026
Study type 3 clinical trials · 2 observational · 3 human data · 1 preclinical · 2 unclassified
Themes 3 themes
-
Cognitive Aging and Alzheimer’s
Alzheimer’s progression is being linked to multimodal biomarkers, cerebrospinal fluid blood–brain barrier dysfunction, and interpretable EEG signals. Cohort work connects cognitive status with ageing, activities of daily living, physical health, and healthy life expectancy. Real-world comparisons are beginning to assess lecanemab against acetylcholinesterase inhibitors. One outlying study concerns WT1 peptide vaccination for pediatric leukemia, making the cluster only partly coherent.
6 papers · 54.5%
-
Metabolic Neuroinflammation and Cognition
Metabolic and inflammatory mechanisms are converging as explanations and biomarker sources for cognitive decline. NLRP3-related neuroinflammation and exosomal miR-223-3p are being examined in people with type 2 diabetes. Brain insulin resistance links obstructive sleep apnea and high-fat-diet exposure to impaired cognition. Population omics studies broaden the search beyond single markers, but validation of predictive signatures remains open.
3 papers · 27.3%
-
Digital Support for Cognitive Health
Digital reminder and monitoring tools are being evaluated as adjuncts for people with mild cognitive impairment and their caregivers. SMART4MD combines reminders, support, and monitoring rather than attempting to replace clinical care. Studies focus on quality of life, adherence, dropout, and quality-adjusted life years over six months. Evidence remains centered on feasibility and user outcomes, with limited evidence for cognitive improvement or durable clinical benefit.
2 papers · 18.2%
Papers
The 11 papers from the last 6 months that study mild cognitive impairment directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cognitive Aging and Alzheimer’s (6)
- Ebetsu Active Future Study (EAFS): cognitive function and physical and mental health in elderly residents of Ebetsu City, Japan - cohort profile. BMJ open · 9 Sept 2026 PMID 42716687
- A cerebrospinal fluid blood-brain barrier dysfunction score is associated with progression from mild cognitive impairment to Alzheimer's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 24 Aug 2026 PMID 42635841
- Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers. Science advances · 12 Aug 2026 PMID 42585316
- Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation. Alzheimer's research & therapy · 23 Jun 2026 PMID 42332768
- WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study. Blood advances · 17 Jun 2026 PMID 42308229
- Evaluating the biological meaning of neural network decisions in EEG-based MCI detection. Journal of neural engineering · 2 Jun 2026 PMID 42229510
Metabolic Neuroinflammation and Cognition (3)
- Exosomal miR-223-3p, associated with NLRP3-related neuroinflammation, as a potential biomarker for mild cognitive impairment in patients with type 2 diabetes mellitus. Journal of Alzheimer's disease : JAD · 17 Sept 2026 PMID 42754564
- Brain insulin resistance: A link between obstructive sleep apnea and cognitive impairment. Journal of diabetes and its complications · 28 Aug 2026 PMID 42664811
- Omics signature of new-onset mild cognitive impairment and dementia in a population-based study. Scientific reports · 16 Jun 2026 PMID 42303781
Digital Support for Cognitive Health (2)
- Effects of the Digital App "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) on People With Mild Cognitive Impairment and Their Informal Caregivers: 18-Month Multicenter Pragmatic Randomized Controlled Trial. Journal of medical Internet research · 24 Jul 2026 PMID 42497412
- Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis. JMIR human factors · 22 May 2026 PMID 42172614
By study type
Clinical trials (3)
- Effects of the Digital App "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) on People With Mild Cognitive Impairment and Their Informal Caregivers: 18-Month Multicenter Pragmatic Randomized Controlled Trial. Journal of medical Internet research · 24 Jul 2026 PMID 42497412
- WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study. Blood advances · 17 Jun 2026 PMID 42308229
- Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis. JMIR human factors · 22 May 2026 PMID 42172614
Observational studies and case reports (2)
- Ebetsu Active Future Study (EAFS): cognitive function and physical and mental health in elderly residents of Ebetsu City, Japan - cohort profile. BMJ open · 9 Sept 2026 PMID 42716687
- A cerebrospinal fluid blood-brain barrier dysfunction score is associated with progression from mild cognitive impairment to Alzheimer's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 24 Aug 2026 PMID 42635841
Human data, design not indexed (3)
- Brain insulin resistance: A link between obstructive sleep apnea and cognitive impairment. Journal of diabetes and its complications · 28 Aug 2026 PMID 42664811
- Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers. Science advances · 12 Aug 2026 PMID 42585316
- Evaluating the biological meaning of neural network decisions in EEG-based MCI detection. Journal of neural engineering · 2 Jun 2026 PMID 42229510
Preclinical: animal, cell and lab studies (1)
- Exosomal miR-223-3p, associated with NLRP3-related neuroinflammation, as a potential biomarker for mild cognitive impairment in patients with type 2 diabetes mellitus. Journal of Alzheimer's disease : JAD · 17 Sept 2026 PMID 42754564
Unclassified: not yet indexed with MeSH (2)
- Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation. Alzheimer's research & therapy · 23 Jun 2026 PMID 42332768
- Omics signature of new-onset mild cognitive impairment and dementia in a population-based study. Scientific reports · 16 Jun 2026 PMID 42303781
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.